Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by JMark80on Nov 14, 2019 8:23pm

87 Views

Post# 30353893

RE:Shiseido and Replicel Have Cured Baldness

Shiseido's patent described a different culturing method, and more importantly creating an immortalized DPC through gene editing.

Here's an abstract published a few years ago from another research team that discovered a method to enable DPC cells to maintain function in vitro.

https://pubs.rsc.org/en/Content/ArticleLanding/2016/TB/C5TB02265G#!divAbstract

Bullboard Posts

Fobi AI responds to cease trade order, filing delay “disappointing”